About

Alison C. Finger has been a director since September 2023 and serves on the Governance and Nominations and Compensation Committees. She has over 30 years of biotech and pharmaceutical leadership experience and has been Chief Operating Officer of Vicero, Inc. since September 2023, after serving as Chief Commercial Officer of bluebird bio from 2015 to 2021 and 21 years at Bristol-Myers Squibb. She holds a B.A. from St. Lawrence University and an M.B.A. from Duke University's Fuqua School of Business.

Roles

Adma Biologics, Inc.
Director · Current role
2023–present
bluebird bio, Inc.
Chief Commercial Officer
August 2015-January 2021
Bristol-Myers Squibb Company
Roles of increasing responsibility (Virology, Neurology, Hematology/Oncology; Managing Director Australia/NZ)
May 1993-May 2014
Decibel Therapeutics (Nasdaq: DBTX)
Board of Directors · Chair of Nominating and Corporate Governance Committee and Audit Committee member; served until the company's acquisition.
December 2021-September 2023
VBL Therapeutics (Nasdaq: VBLT)
Board of Directors
July 2021-August 2022

External Roles

Vicero, Inc.
Chief Operating Officer
—
KeifeRx LLC
Independent Director
—

Director Compensation

FY 2025
Fees earned or paid in cash
$66,250
Stock awards (RSUs)
$174,986
10,889 RSUs granted 2/19/2025
Option awards
$174,999
16,279 options, $16.07 exercise price

Also at Adma Biologics, Inc.

Colleague
Adam S. Grossman
Founder, President, Chief Executive Officer and Director
Colleague
Kaitlin Kestenberg
Chief Operating Officer and Senior Vice President, Compliance
Colleague
Paul Terence Kohler, Jr.
Chief Financial Officer and Treasurer

Related

Company
Adma Biologics, Inc.
Company hub

See how VectorShift works for your firm

Request Demo